Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Leases (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Operating Leases for 4 consecutive years, with $936000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 44.52% to $936000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $936000.0 through Dec 2025, down 44.52% year-over-year, with the annual reading at $936000.0 for FY2025, 44.52% down from the prior year.
  • Operating Leases for Q4 2025 was $936000.0 at Orchestra BioMed Holdings, down from $1.1 million in the prior quarter.
  • The five-year high for Operating Leases was $1.7 million in Q4 2024, with the low at $936000.0 in Q4 2025.
  • Average Operating Leases over 4 years is $1.3 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Operating Leases soared 62.52% in 2024, then crashed 44.52% in 2025.
  • Over 4 years, Operating Leases stood at $1.7 million in 2022, then crashed by 38.32% to $1.0 million in 2023, then skyrocketed by 62.52% to $1.7 million in 2024, then plummeted by 44.52% to $936000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $936000.0, $1.1 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.